Madrigal Pharmaceuticals

MDGL Large Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$546.89

+3.22% today

52W: $265.00 – $615.00

52W Low: $265.00 Position: 80.5% 52W High: $615.00

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

42.75x

Forward Price/Earnings

P/S Ratio

13.09x

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$12.5B

Market Capitalization

Revenue Growth

210.8%

YoY Revenue Growth

Profit Margin

-30.08%

Net profit margin

ROE

-42.49%

Return on Equity

Beta

—

Market sensitivity

Short Interest

19.76%

% of float sold short

Avg. Volume

380,393

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Strong Buy

14 analysts

Avg. Price Target

$668.57

+22.25% upside

Target Range

$529.00 – $964.00

About the Company

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 915 Exchange: NMS